Search research articles
Contact Us
Filters
Showing results (71-80 of 98) with videos related to
Page
of 10
Sort By:
Clinical Colorectal Cancer
|
April 12, 2015
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study
Nicola Personeni, Lorenza Rimassa, Claudio Verusio, et al.
Clinical and Experimental Rheumatology
|
March 28, 2025
Systemic vasculitis: one year in review 2025
Paolo Delvino, Chiara Baldini, Martina Bonacini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2022
Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials
Niki Christou, Elisabeth S Bergen, Clemence Canton, et al.
Clinical Lung Cancer
|
August 1, 2020
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study
Diego Cortinovis, Federica Grosso, Luciano Carlucci, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2017
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients
Stefano Cascinu, Gerardo Rosati, Guglielmo Nasti, et al.
Journal of the American Academy of Dermatology
|
November 17, 2016
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases
Mario Mandalà, Francesca Galli, Laura Cattaneo, et al.
British Journal of Cancer
|
July 31, 2018
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma
Angiolo Gadducci, Federica Grosso, Giovanni Scambia, et al.
International Journal of Cancer
|
September 3, 2022
Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection
Nicla La Verde, Agostino Riva, Maria Silvia Cona, et al.
Cancer Medicine
|
April 28, 2023
Clinical efficacy of the first two doses of anti-SARS-CoV-2 mRNA vaccines in solid cancer patients
Maria Silvia Cona, Agostino Riva, Davide Dalu, et al.
British Journal of Cancer
|
September 21, 2019
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
Nicoletta Colombo, Eleonora Zaccarelli, Alessandra Baldoni, et al.
Page
of 10
Search research articles
Search
Showing results (71-80 of 98) with videos related to
Sort By:
Page
of 10
Clinical Colorectal Cancer
|
April 12, 2015
FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study
Nicola Personeni, Lorenza Rimassa, Claudio Verusio, et al.
Clinical and Experimental Rheumatology
|
March 28, 2025
Systemic vasculitis: one year in review 2025
Paolo Delvino, Chiara Baldini, Martina Bonacini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 13, 2022
Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials
Niki Christou, Elisabeth S Bergen, Clemence Canton, et al.
Clinical Lung Cancer
|
August 1, 2020
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study
Diego Cortinovis, Federica Grosso, Luciano Carlucci, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2017
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients
Stefano Cascinu, Gerardo Rosati, Guglielmo Nasti, et al.
Journal of the American Academy of Dermatology
|
November 17, 2016
Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases
Mario Mandalà, Francesca Galli, Laura Cattaneo, et al.
British Journal of Cancer
|
July 31, 2018
A phase II randomised (calibrated design) study on the activity of the single-agent trabectedin in metastatic or locally relapsed uterine leiomyosarcoma
Angiolo Gadducci, Federica Grosso, Giovanni Scambia, et al.
International Journal of Cancer
|
September 3, 2022
Immunogenicity of two doses of BNT162b2 and mRNA-1273 vaccines for solid cancer patients on treatment with or without a previous SARS-CoV-2 infection
Nicla La Verde, Agostino Riva, Maria Silvia Cona, et al.
Cancer Medicine
|
April 28, 2023
Clinical efficacy of the first two doses of anti-SARS-CoV-2 mRNA vaccines in solid cancer patients
Maria Silvia Cona, Agostino Riva, Davide Dalu, et al.
British Journal of Cancer
|
September 21, 2019
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
Nicoletta Colombo, Eleonora Zaccarelli, Alessandra Baldoni, et al.
Page
of 10